In 2017, the Down Syndrome market size in the seven major markets was USD 662.9 million, which is expected to increase during the forecast period. The total diagnosed Down syndrome prevalent population in the seven major market countries ( (i.e the United States, EU5 (the UnitedKingdom, Germany, Italy, France, and Spain) and Japan.) was 699,750 in 2017.
The absence of approved products in the Down Syndrome market makes the treatment process more complex, and the disease is associated with numerous health problems and high healthcare costs. However, worldwide many companies are exploring various drugs to find efficient therapy for the treatment of Down syndrome, some of the key companies include AC Immune, Annovis Bio, Alzheon, Balance Therapeutics, OPKO Health, Transition Therapeutics, and many others.
For more details, visit: https://www.delveinsight.com/blog/down-syndrome-market-prevalence/